Skip to content

Author

E. Bayram

We have 5 of 28 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

EZH2 expression in diffuse large B-cell lymphoma: clinicopathological associations and relationship with survival

Purpose: Enhancer of zeste homolog 2 (EZH2) is an epigenetic regulator implicated in the pathogenesis of diffuse large B-cell lymphoma, but the prognostic value of its protein expression is uncertain. We evaluated EZH2 expression and its associations with clinicopathological features and survival.Materials and Methods:...

Mehmet Mutlu Kıdı, Mehmet Turker, Sedat Biter et al. · 0 citations
Open access Oct 2026

Prognostic Significance of CD47 and DHX9 in Metastatic Rectal Cancer

Background/Objectives: The prognosis of metastatic rectal cancer remains poor, and few reliable prognostic biomarkers are available. DHX9 and CD47 have been implicated in colorectal cancer biology, but their prognostic value in metastatic disease remains unclear. We evaluated the associations of DHX9 and CD47 expressio...

Ş. Yaslıkaya, Ş. A. İpek, T. Toyran et al. · 0 citations
Open access Sep 2026

Prognostic Value of Pretreatment Modified Glasgow Prognostic Score in Nivolumab-Treated Advanced Non-Small Cell Lung Cancer

Background/Objectives: Immune checkpoint inhibitors have become a standard treatment option for advanced/metastatic non-small cell lung cancer (NSCLC); however, considerable heterogeneity exists among patients regarding treatment response and survival. This study aimed to determine whether the pretreatment modified Gla...

Sedat Biter, Mehmet Mutlu Kıdı, Yasemin Aydınalp Camadan et al. · 0 citations
Review Open access Sep 2026

Clinicopathological Features, Treatment Modalities, and Prognostic Factors of Leptomeningeal Carcinomatosis in Patients with Breast Cancer: A Single-Center Retrospective Analysis

Aim: Leptomeningeal metastasis (LM) from breast cancer carries a poor prognosis, and most published cohorts originate from high-volume referral centers. We aimed to identify factors associated with overall survival (OS) after an LM diagnosis in routine practice and to describe diagnostic and treatment patterns.Methods:...

Mehmet Mutlu Kıdı, Omer Kaya, Sedat Biter et al. · 0 citations
Open access Aug 2026

EZH2 Expression and Clinical Outcomes in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Retrospective Cohort Study

These exploratory findings do not support the clinical use of EZH2 as a biomarker at this stage; prospective, multicenter studies using predefined thresholds and standardized immunohistochemical methods are needed to clarify its potential role as a marker complementary to PD-L1.

E. Asarkaya, Hatice Asoğlu, Abdurrahman Aykut et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.